Sato launches motion-sickness thin-strip solution
TORRANCE, Calif. — Sato Pharmaceutical on Wednesday launched Zentrip, a new motion-sickness product featuring a fast-dissolving, fast-acting, citrus-flavored meclizine hydrochloride thin-strip.
"In only 15 seconds, this low-cost solution is working to prevent and ease the very uncomfortable effects of motion sickness," stated Walter Morimoto, sale manager for Sato. “Motion sickness is often the result of slow movement or movement in two directions — such as back and forth and up and down, at the same time — much as fishermen have experienced. As many have found, severity of this experience can last for hours or up to several days."
Zentrip offers up to eight hours of relief, Morimoto suggested.
Zentrip’s main ingredient is meclizine hydrochloride, an anti-emetic that works by blocking a chemical messenger in the brain, helping to reduce or prevent vomiting and other sensations associated with motion sickness, such as dizziness.
Because meclizine is an antihistamine and anticholinergic, it should be taken only by adults and those older than 12 years of age. Best results are found by taking the medication about one hour prior to traveling.
Suggested retail price ranges between $4.99 and $5.99.
Reckitt Benckiser posts third online video game to entice prospective employees
PARSIPPANY, N.J. — Reckitt Benckiser on Thursday unveiled Turbo RACER, a new free online game and a free mobile racing-game app available on iTunes, as part of the company’s corporate awareness program. The game is designed to metaphorically underscore the essence of working at RB.
Turbo RACER is RB’s third launch in a series of such online games as PoweRBrands and Urban Thrill. With each of these mobile games, RB hopes to further engage its target audience: students and those driven young professionals who are early on in their careers. The successful April launch of Urban Thrill, which is based on the cityscape sport of freerunning, has already been played by more than 490,000 users in the first three months.
RB chose a racing platform for this newest game to help reinforce the company’s rapid-paced corporate culture. "I often describe our culture at RB the same way I would describe a Formula 1 racing car: all engine, all go. Very fast-moving, but no frills and no cruise-control button," stated Andraea Dawson-Shepherd, SVP global corporate communications at RB.
Go to Turbo-Racer.com to download the game.
Endo ends axomadol collaboration with Grunenthal
CHADDS FORD, Pa. — Endo Pharmaceuticals has ended its research program and collaboration with Grunenthal.
The announcement comes shortly after the companies revealed their mid-stage clinical trial results for axomadol — designed to treat chronic low back pain — did not meet the predetermined endpoint.
Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.
"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," Endo Pharmaceuticals EVP research and development Ivan Gergel said. "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."